Anxiety and Depression IV novel targets Flashcards

1
Q

what is the effectiveness of anxiolytics and antidepressants

A

30% patients have minimal benefits from BZDs/SSRIs
30% experience no benefits from antidepressants
high placebo response rates (30%)
risk of suicide
trials use less severely depressed patients (ethical reasons)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what do current treatments lack

A

progress
understanding of neurobiology of anxiety and depression
underlying cellular/molecular pathogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pharmacogenetics

A

study of genetic variations that lead to individual variations in the drug effect (efficacy) and adverse effect profile (toxicity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

pharmacodynamics

A

what the drug does to the body
effect of the drug on the target organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

pharmacokinetics

A

what the body does to the drug
drug absorption/distribution/metabolism/excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

drug metabolism

A

Phase I (cytochrome P450 enzymes) increase polarity (more likely to be rejected) oxidation/reduction/hydrolysis
phase II - conjugation with an endogenous substance (methyl)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

drug metabolising enzymes (DMEs) PK

A

P450 enzymes: CYP2D6/CYP2C19 metabolises antidepressants - highly polymorphic genes
affect response of TCAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DME classifications

A

PM - poor metabolising linked to adverse effects (increased plasma levels = increased toxicity) dose correction via CYP gene
IM - intermediate metabolism
EM - extreme metabolism
UM - ultrarapid metabolism (treatment resistance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

p-glycoprotein

A

transports drugs across the BBB
reduces uptake of some antidepressants (citalopram/amitriptyline/paroxetine/venlafaxine)
3 functional variants: c3435T/c1236/g262T), SNPs with drug response, faulty p-gp associated with better drug response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5HT transporter
PD

A

target for SSRI (TCAs)
SLC6A4 encodes transporter - contains 2 polymorphisms (5HTTLPR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

NA transporter PD

A

TCA target
transporter SLC6A4 affects response to TCAs
SNP: rs36029

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

5HTTLPR

A

S allele involved in depression aetiology (depressive symptoms/clinical depression/suicidality only with stress/childhood maltreatment)
S allele involved in poor response to psychological treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Piquette-Miller & Grant (2007)

A

individuals with same diagnosis
non/toxic responders given alternative drug/dose
no toxicity responders given conventional dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

pros and cons of personalised medicine

A

pro: simple/helps clinicians to pick patients which respond to treatment/understand genetics of responders
cons: what do doctors do with non-responders?/responders do better with other treatment/co-founded by spontaneous remission/placebo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

metabotropic glutamate receptors

A

type 1: mGlu1/5 - postsynaptic excitatory terminals in limbic areas
type 2: mGlu2/3 - presynaptic excitatory terminals in limbic areas
mGluR5 antagonist - fenobam - effective in animal models/GAD/panic attacks - psychostimulant side effect
mGluR2/3 agonist (LY354740/LY544344) - good efficacy/convulsants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

NMDAR antagonism

A

delay in therapeutic effect of current antidepressants (increased risk of suicide) loss of synaptic connections
ketamine (fast acting antidepressant) anaesthetic/analgesic/quickest response (40min up to 10 day post infusion) subanaesthetic conc gives rapid antidepressant in rodent/patients (Berman et al., 2000) - enhances neuroplasticity (blocks GABA release/blocks mTOR activation)

17
Q

HPA axis

Hyman (2009)

A

PVN releases CRH
ACTH release
AC releases glucocorticoid
stress response regulation (negative feedback)

18
Q

a/d patients and HPA axis

A

HPA axis hyperactivity/increased cortisol
abnormal function of glucocorticoid receptor (imparied GR mediated feedback inhibition)
dexamethasone suppression test impaired ~50% depressed patients
detrimental effect on limbic brain structures

19
Q

HPA drugs

A

FKBP5 antagonist - SAFit1/2 - FKBP5 regulates response of GRs and HPA axis
GR antagonist (mifepristone) GRs in hippocampus/PVN/AP inhibit further CRH release
CRH1 R antagonist (R121919) - reduces cortisol release in response to stress w/o inhibiting CRH-induced release of ACTH (retains responsiveness to CRH)

20
Q

inflammatory system

A

increased cytokines in depression (IL-6/TNF-a/C-reactive protein)
cytokines produce symptoms which overlap with depression (fatigue/loss of appetite/anxiety/sickness behaviour)
increased inflammation in childhood maltreatment/adult life stress
cytokines normalised with antidepressants

21
Q

cytokines and NT metabolism

A

cytokines activate kynurenine pathway
converts 5HT precursor (tryptophan) to neurotoxic end products (deplete 5HT)

22
Q

how to alter the HPA axis

A

cytokines decrease GR expression - prevent translocation of GR into nucleus (disturb feedback inhibition) adjunction with NSAIDS to increase remission/response
antibiotics to improve depressive symptoms
gut-microbiome (carlessi et al., 2022) - leaky gut releases pro-inflammatory molecules

23
Q

epigenetics

A

causal interaction between genes and their products, bring the phenotype into being
regulate chromatin structure and gene expression/histone &chromatin remodeling/DNA methylation of cytosine/non-coding RNA mediated gene silencing

24
Q

environmental effects of epigenetics

A

severe childhood trauma - DNA methylation in GR regulating protein (FKBP5)/linked to HPA abnormalities/psychiatric disorders
rodent model of decreased maternal care - increases DNA methylation of GR exon 17 promoter/decreased histone K9 acetylation/reverse HDAC inhibitor,trichostatin A
rodent model of chronic defeat stress - decreased histone acetylation in hippocampus - reversed by antidepressants

25
new directions for epigenetics
use HDAC inhibitors (imipramine) as antidepressants Boks et al., 2012
26
multimodal vs monomodal approach
wilkinson et al., 2019 multimodel is synergistic (preferred)
27
opposing neuromodulatory role of endocannabinoid system
DSI - depolarisation induced suppression of inhibition DSE - depolarisation induced suppression of excitation CB1 (most common receptor-GPCR) CB1 antagonism has mixed effects in animal studies studies (target endocannabinoid ost-release uptake and degrade) promising preclinical finsigs for anandamine transporter blocker and inhibitor of fatty acid amide hydrolase
28
neuropeptides | located in brain areas implicated in anxiety
CCK - CCK2 R ant clinical trials unsuccesful NPY - anxiolytic effect - no drug targetting NPY in clinical trials Tachykinins - NK1/NK2 R ant anxiolytic - inconclusive clinical trials OT - emotions (fear/anxiety/stress) intranasal spray (clincial trials)
29
adult hippocampal neurogenesis
formation of new neurons from hippocampal SCs (SVZ/SGZ) levels of DG neurogenesis correlate to hippocampal dependent learning tasks decreased hippocampal neurogenesis in depressed patients and animal models
30
enhancing neurogenesis
antidepressants promote neurogenesis functional integration of new neurons (6-8 weeks) delay in changing neuronal function/circuitry develop drugs which promote hippocampal neurogenesis e.g. BDNF